Rubius Therapeutics
Biotechnology Research • 
Cambridge, Massachusetts, United States • 11-20 Employees
Company overview
| Headquarters | 399 Binney St, Suite 300, Cambridge, Massachusetts 02139, US |
| Phone number | +16176799600 |
| Website | |
| NAICS | 541714 |
| SIC | 283 |
| Keywords | Science, Oncology, Platform, Biotech, Autoimmune, Red Blood Cell |
| Founded | 2014 |
| Employees | 11-20 |
| Socials |
Key Contacts at Rubius Therapeutics
James Carmichael
Director
Brenda Hugh
Associate Director Supply Chain, Sourcing
Rubius Therapeutics Email Formats
Rubius Therapeutics uses 5 email formats. The most common is {first name}.{last name}@company.com (e.g., john.doe@company.com), used 42.1% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name}@company.com | john.doe@company.com | 42.1% |
{first name}@company.com | john@company.com | 25.3% |
{first name initial}{last name}@company.com | {first name initial}doe@company.com | 14.8% |
{first name}{last name}@company.com | johndoe@company.com | 10.2% |
{last name}@company.com | doe@company.com | 7.6% |
About Rubius Therapeutics
Rubius Therapeutics is a biopharmaceutical company pioneering a new era of cellular medicines. Our proprietary RED PLATFORM™ was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and ready to-use cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Our initial focus is to advance RCT™ product candidates for the treatment cancer and autoimmune diseases by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. We are currently enrolling patients in a Phase 1/2 clinical trial of RTX-240; the trial has two Phase 1 arms enrolling adult patients with advanced solid tumors: an ongoing monotherapy dose escalation arm in adults with relapsed/refractory or locally advanced solid tumors and a combination therapy dose escalation arm with pembrolizumab in adults with relapsed/refractory or locally advanced solid tumors. In April 2022, the combination arm with pembrolizumab was expanded to focus on non-small cell lung cancer and renal cell carcinoma patients. We are also enrolling patients in a Phase 1/2 clinical trial of RTX-224 for the treatment of patients with certain advanced solid tumors, including non-small cell lung cancer, cutaneous melanoma, head and neck squamous cell carcinoma, urothelial (bladder) carcinoma and triple-negative breast cancer.
Rubius Therapeutics revenue & valuation
| Annual revenue | $87,500,000 |
| Revenue per employee | $4,375,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $280,000,000 |
| Total funding | $200,000,000 |
Employees by Management Level
Total employees: 11-20
Seniority
Employees
Employees by Department
Rubius Therapeutics has 10 employees across 3 departments.
Departments
Number of employees
Rubius Therapeutics Tech Stack
Discover the technologies and tools that power Rubius Therapeutics's digital infrastructure, from frameworks to analytics platforms.
Hosting
CMS
Miscellaneous
JavaScript frameworks
JavaScript frameworks
Miscellaneous
Live chat
United Kingdom
Spain
Canada
France
Ireland
Frequently asked questions
4.8
40,000 users
